TO PLACE YOURORDER CONTACT:
(kit for the preparation of technetium Tc 99m mertiatide)
CLARITYImage quality aids in patient diagnosis
CLEARANCESingle 30-minute procedure delivers renal flow and function results3,4
CONFIDENCEDelivers information you need to help you feel confident about your diagnosis
INDICATIONS AND USAGE
IMPORTANT RISK INFORMATION WARNINGS AND PRECAUTIONS
USE IN SPECIFIC POPULATIONS
1. AMR/Arlington Medical Resources, Inc., The U.S. Imaging Market Guide, Jul–Dec 2010.2. Taylor A, Nally JV. Clinical Applications of Renal Scintigraphy. AJR 1995; 164: 31-41.3. Taylor A, Blaufox MD, Dubovsky EV, Fine EJ, Fomei E, et al. Society of Nuclear Medicine procedure guideline for diagnosis of renovascular hypertension 3.0. Procedureguidelines, Policy and Practice, http://interactive.snm.org/docs/pg_ch16_0403.pdf, 2003.4. Dubovsky E, Russell C, et al. Report of the Radionuclides in Nephrourology Committee for Evaluation of Transplanted Kidney. Seminars in Nuclear Medicine 1999; 29: 175-188.5. Wellman HN, Milgrom M. Assessment of Renal Transplant Patients with Tc-99m MAG3: Case Reports and review. Dialysis & Transplantation 1992, Vol. 21(11), pp. 720-736.
Mallinckrodt, the “M” brand mark, and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners. © 2015 Mallinckrodt.
Mallinckrodt Pharmaceuticals is a registered business name of Mallinckrodt plc, which is registered in Ireland as a public limited company with registration number 522227 and has its registered office at Damastown, Mulhuddart, Dublin 15, Ireland.